摘要
目的检测细胞分裂周期蛋白25B(CDC25B)在三阴性浸润性导管癌中的表达情况,分析其与三阴性浸润性导管癌预后的相关性。方法应用免疫组化染色技术检测92例三阴性浸润性导管癌石蜡标本中的CDC25B表达情况,并分析其与三阴性浸润性导管癌患者的年龄、TMN分期、淋巴结转移以及预后间的关系。结果三阴性浸润性导管癌中CDC25B高表达率为39.1%(36/92);CDC25 B高表达与腋窝淋巴结癌转移情况、TNM分期、年龄、病理学类型、肿瘤大小均无统计学意义相关,CDC25B高表达组的总生存率、无病生存率均显著低于低表达组(P<0.05)。Cox多因素分析结果显示CDC25B表达及腋窝淋巴结为无病生存率的独立预测因素。结论三阴性浸润性导管癌中CDC25B存在高表达,与乳腺癌的发展及预后有关,检测CDC25B对三阴性浸润性导管癌治疗及预后评估有一定参考意义。
Objective To examine the expression of CDC25B and to evaluate its role as a prognostic marker in treating triple negative invasive ductal breast cancer.Method 92 cases of triple negative invasive ductal breast cancer were first subjected to immunohistochemical test for information of the expression of CDS25B.Its relationship with other variables such as the patient’s age, TNM staging, axillary lymph node metastasis, and prognosis were then analyzed.Findings In triple negative invasive ductal breast cancer, 39.1% of cases showed high expression of CDC25B （36/92）.The expression of CDC25B was found to have no significant relationship with axillary lymph node metastasis, TNM staging, age, pathologic type or tumor size.The overall survival and disease-free survival rates of the high expression group was significantly lower than those of the low expression group （P〈0.05）.Cox multi-factor analysis showed that CDC25B expression and axillary lymph node status were independent prognostic factors of disease-free survival.Conclusion Over-expression of CDC25B was found in triple negative invasive ductal breast cancer and to correlate with the development and prognosis of breast cancer.The expression of CDC25B can serve as a significant prognostic marker in the treatment of breast cancer.
出处
《健康研究》
CAS
2015年第4期382-385,共4页
Health Research
基金
嘉兴市科技计划项目(2012AY1070-3)
